临床试验/NL-OMON21435

NL-OMON21435招募中不适用

Third population-based immune surveillance study used for the evaluation of immunity against SARS-CoV-2

ational Institute for Public Health and the Environment (RIVM)0 个研究点目标入组 14,000 人开始时间: 待定最近更新: 2024年6月11日

适应症

试验速览

阶段: 不适用
状态: 招募中
发起方
入组人数: 14,000

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

https://pubmed.ncbi.nlm.nih.gov/33632374/ https://pubmed.ncbi.nlm.nih.gov/33624751/ https://pubmed.ncbi.nlm.nih.gov/33249407/ https://pubmed.ncbi.nlm.nih.gov/33772265/ https://pubmed.ncbi.nlm.nih.gov/34114187/

研究设计

研究类型: Observational

入排标准

入选标准

•Subject previously participated in the PIENTER 3 study (2016/17) and had indicated that they could be approached for a follow-up study, or Subjects from a random age-stratified sample from the Netherlands

排除标准

•There are no exclusion criteria.

研究者

发起方

ational Institute for Public Health and the Environment (RIVM)

相似试验

Third population-based immune surveillance study used for the evaluation of immunity against SARS-CoV-2COVID-19SARS-CoV-210047438

NL-OMON52416RIVM11,229

Third population-based immune surveillance study for the evaluation of the National Immunisation Programme in the Netherlands: the PIENTER3 studyimmune systemprotection against infectious diseases10019815

NL-OMON42468RIVM8,400

PIENTER-onderzoekThe age-specific seroprevalence (immunity) for diseases included in the NIP of the Dutch general population

NL-OMON24544ational Institute for Public Health and the Environment (RIVM)8,400

Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of QIVc in Subjects ≥2 to <18 Years of AgeInfluenza, Human

NCT03165617Seqirus4,514

进行中（未招募）

?Ensayo clínico en fase III para estudiar la inmunogenicidad, tolerabilidad y uniformidad de fabricación de V503 (vacuna polivalente de partículas viroides [PV] L1 del virus del papiloma humano [VPH]) en preadolescentes y adolescentes (de 9 a 15 años) y en comparación con mujeres jóvenes (de 16 a 26 años).A Study to Demonstrate Immunogenicity, Tolerability, and Manufacturing Consistency of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered in Preadolescents and Adolescents (9 to 15 year olds), with a Comparison to Young Women (16 to 26 year olds)Cancer CervicalCervical CancerMedDRA version: 12.0Level: LLTClassification code 10063001Term: Human papilloma virus infection

EUCTR2009-011617-25-ESMerck & Co., Inc.3,074